HC Wainwright Issues Pessimistic Estimate for Cibus Earnings

Cibus, Inc. (NASDAQ:CBUS – Free Report) – Equities research analysts at HC Wainwright dropped their FY2030 EPS estimates for shares of Cibus in a report issued on Friday, November 13th. HC Wainwright analyst A. Dayal now forecasts that the company will post earnings per share of $2.05 for the year, down from their prior forecast of $2.08. The consensus estimate for Cibus’ current full-year earnings is ($1.13) per share.

Several other equities research analysts also recently issued reports on the stock. Wall Street Zen downgraded shares of Cibus from a “hold” rating to a “sell” rating in a research note on Saturday, October 17th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Cibus in a report on Friday, September 25th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Cibus currently has an average rating of “Hold” and an average target price of $9.00.

View Our Latest Stock Analysis on Cibus

Cibus Stock Performance

Shares of CBUS stock opened at $1.13 on Monday. The firm’s 50-day moving average is $1.43 and its 200-day moving average is $1.82. The stock has a market cap of $86.37 million, a price-to-earnings ratio of -0.75 and a beta of 1.65. Cibus has a 52-week low of $1.02 and a 52-week high of $4.19.

Cibus (NASDAQ:CBUS – Get Free Report) last announced its quarterly earnings data on Thursday, November 12th. The company reported ($0.29) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.09). The firm had revenue of $0.80 million during the quarter, compared to the consensus estimate of $1.30 million. Cibus had a negative net margin of 2,131.38% and a negative return on equity of 526.66%.

Institutional Investors Weigh In On Cibus

A number of institutional investors have recently made changes to their positions in CBUS. StoneX Group Inc. increased its position in Cibus by 115.9% during the 3rd quarter. StoneX Group Inc. now owns 30,605 shares of the company’s stock worth $50,000 after buying an additional 16,430 shares during the period. Dimensional Fund Advisors LP bought a new stake in shares of Cibus in the first quarter valued at about $33,000. Nautilus Advisors LLC bought a new stake in shares of Cibus in the third quarter valued at about $35,000. Renaissance Technologies LLC boosted its position in shares of Cibus by 42.5% in the first quarter. Renaissance Technologies LLC now owns 98,900 shares of the company’s stock valued at $196,000 after acquiring an additional 29,500 shares during the period. Finally, Rockland Trust Co. bought a new stake in shares of Cibus in the second quarter valued at about $41,000. Institutional investors own 33.81% of the company’s stock.

About Cibus

(Get Free Report)

Cibus is an agricultural technology company that develops plant traits using gene-editing technologies. Its proprietary Rapid Trait Development System (RTDS) is designed to make precise changes to a plant’s own genes, with the goal of developing useful crop characteristics without adding foreign DNA. The company’s research and development focuses on traits for crops including canola, rice and wheat, such as herbicide tolerance and resistance to crop diseases. Cibus aims to bring these traits to market through seed and technology licensing arrangements with partners in the agricultural industry.

Recommended Stories

Earnings History and Estimates for Cibus (NASDAQ:CBUS)

Receive News & Ratings for Cibus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cibus and related companies with MarketBeat.com's FREE daily email newsletter.